Zobrazeno 1 - 10
of 116
pro vyhledávání: '"Andrew Belch"'
Autor:
Nizar J. Bahlis, Thierry Facon, Matthew C. Cheung, Axel Tosikyan, Kevin W. Song, Andrew Belch, Christine Chen, Darrell White, Kenneth C. Anderson, Shankar Srinivasan, Suzanne Robinson, Angela Dispenzieri, Chaim Shustik, Diane Brown
Publikováno v:
Cancer Medicine
The phase 3 FIRST trial demonstrated significant improvement in progression‐free survival (PFS) and overall survival (OS) with an immune‐stimulatory agent, lenalidomide, in combination with low‐dose dexamethasone until disease progression (Rd c
Autor:
Bernardo Garichochea, Judit Demeter, Yuankai Shi, Umberto Vitolo, Enrica Morra, Margarida Marques, Miklos Egyed, Toshiki Uchida, Árpád Illés, Kenichi Ishizawa, Cristina Ligia Cebotaru, Ashis Mukhopadhyay, Masafumi Taniwaki, Sung-Soo Yoon, Cristina-Ligia Truica, Cheol Won Suh, Irina Lysenko, Naokuni Uike, Huaqing Wang, Achiel Van Hoof, Maryna Kyselyova, Osmanov Ea, Andrew Belch, Alexy Kuzmin, Caballero Gabarrón, Steven Van Steenweghen, Sergio Cancelado, Olga Samoilova, Kensei Tobinai, Kiyoshi Ando, Susumu Nakahara, Tatiana Scheider, Massimo Federico, Dmitry Udovitsa, Xiaoyan Ke, Yurii Lorie, Tatsu Shimoyama, Weerasak Nawarawong, Sebastian Grosicki, Gregor Verhoef, Nuriet Khuageva, Suporn Chuncharune, Fritz Offner, Albert Oriol Rocafiguera, Charles Farber, Ernst Späth-Schwalbe, Juliana Pereira, Ting Liu, Lee-Yung Shih, Steven Le Gouill, Miklos Udvardy, Richard Greil, Carmen Cao, Tomohiro Kinoshita, Horia Bumbea, Yasuhito Terui, Eva Gonzalez-Barca, Irina Bulavina, Peter Hu, Francisco Javier Capote, Olga Serduk, Akihiro Tomita, Ilseung Choi, Mahmut Gumus, Udomsak Bunworasate, Adriana Teixeira, Vladimir Merkulov, Yeow Tee Goh, Tadeusz Robak, Huiqiang Huang, Jie Jin, Cristina Ileana Burcoveanu, Halyna Pylypenko, Joaquín Díaz, Herlander Marques, Zoltán Gasztonyi, Vijay Rao Phooshkooru, Gayane Tumyan, Maike De Wit, Ali Khojasteh, Marcelo Capra, Vladimir Lima, Dai Maruyama, Viacheslav Pavlov, Georg Heß, Carmino Antonio De Souza, Zhao Wang, Iryna Kryachok, Amel Mezlini, Galvez Cardenas, Marina Golubeva, Lyudmila Kuzina, Patricia Santi, Remy Gressin, Balkis Meddeb, Xiaonan Hong, David Belada, Bernard De Prijck, Jan Maciej Zaucha, Jiri Mayer, Michinori Ogura, Rumiko Okamoto, Dolores, Irit Avivi, Mario Ojeda-Uribe, Grigoriy B Rekhtman, Jun Zhu, Reyes Arranz, Polina Kaplan, André Bosly, Ann Van De Velde, Kenny Mauricio, Yuri Dunaev, Anatoly Golenkov, Oleg Gladkov, Yoshiharu Maeda, Franco Cavalli, Dina Ben Yehuda, Michele Baccarani, Markus Raderer, Razvan Stoia, Carlos Appiani, Zvenyslava Masliak, Zita Borbenyi, Guiseppe Rossi, Julia Alexeeva, Johannes Drach, Kateryna Vilchevskaya, Georgii Manikhas, Jan Novák, Noppadol Siritanaratkul, Zhixiang Shen, Alexander Suvorov, Michael Crump, Pierre Zachee, Ofer Shpilberg, Sepideh Nemat, Mitsutoshi Kurosawa, Sreejith Nair, Bulent Undar, Govind Babu, Kudrat Abdulkadryrov, Adriana Sheliga
Publikováno v:
The Lancet Oncology. 19:1449-1458
Summary Background In the LYM-3002 study, the efficacy and safety of frontline bortezomib plus rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) and rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) were c
Autor:
Maria Roussou, Michel Delforge, Vania Hungria, G. Bries, Don Robinson, Anne-Marie Stoppa, Anna Potamianou, M. Spencer, Javier de la Rubia, Jesper Aagesen, Deniz Sargin, Evangelos Terpos, Lucia Ahlberg, Joris Diels, Cyrille Hulin, Meletios A. Dimopoulos, Andrew Belch, Robert Olie, Helgi van de Velde, Eirini Katodritou
Publikováno v:
European Journal of Haematology. 101:556-565
Objective The efficacy and safety of bortezomib-based therapy for relapsed/refractory multiple myeloma (RRMM) in clinical trials may differ from the oncology practice experience. The electronic VELCADE® OBservational Study was designed to prospectiv
Autor:
Jacob P. Laubach, Niels W.C.J. van de Donk, Tahamtan Ahmadi, Andrew Belch, Nizar J. Bahlis, Torben Plesner, Peter M. Voorhees, Clarissa M. Uhlar, Huaibao Feng, Paul G. Richardson, Sagar Lonial, Ming Qi, Jianping Wang, Brendan M. Weiss, Hareth Nahi, Saad Z. Usmani
Publikováno v:
Usmani, S Z, Nahi, H, Plesner, T, Weiss, B M, Bahlis, N J, Belch, A, Voorhees, P M, Laubach, J P, van de Donk, N W C J, Ahmadi, T, Uhlar, C M, Wang, J, Feng, H, Qi, M, Richardson, P G & Lonial, S 2020, ' Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma : final results from the phase 2 GEN501 and SIRIUS trials ', The Lancet Haematology, vol. 7, no. 6, pp. e447-e455 . https://doi.org/10.1016/S2352-3026(20)30081-8
The Lancet Haematology, 7(6), e447-e455. Lancet Publishing Group
The Lancet Haematology, 7(6), e447-e455. Lancet Publishing Group
Summary Background Daratumumab showed encouraging efficacy as monotherapy in patients with heavily pretreated multiple myeloma in the GEN501 and SIRIUS studies. Here we report a pooled, post-hoc final analysis of these two studies. Methods GEN501 was
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ff9287699020810f638c78fcf43e906
https://research.vumc.nl/en/publications/2d5388d9-2ada-497b-a6e7-d98a23946662
https://research.vumc.nl/en/publications/2d5388d9-2ada-497b-a6e7-d98a23946662
Autor:
Anne Banos, Michel Attal, Salomon Manier, Christine Chen, Jin Lu, Javier de la Rubia, Andrew Belch, Michele Cavo, Angela Dispenzieri, Mourad Tiab, John Catalano, Guang Chen, Lugui Qiu, Aurore Perrot, Je-Jung Lee, Katja Weisel, Hervé Avet-Loiseau, Vanessa Houck, Philippe Moreau, Murielle Roussel, Thierry Facon, Nizar J. Bahlis, Heinz Ludwig, Kenneth C. Anderson, Antonello Pinto, Catarina Geraldes, Xavier Leleu, Bertrand Arnulf, Annette Ervin-Haynes, Albert Oriol, Lotfi Benboubker, Meletios A. Dimopoulos, Daniel Binder, Eileen M Boyle, Cyrille Hulin, Darrell White, Jamie D. Cavenagh, Michel Delforge, Mohamad Mohty
Publikováno v:
BLOOD
r-FISABIO. Repositorio Institucional de Producción Científica
instname
r-FISABIO: Repositorio Institucional de Producción Científica
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
Blood
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
r-FISABIO. Repositorio Institucional de Producción Científica
instname
r-FISABIO: Repositorio Institucional de Producción Científica
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
Blood
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
This FIRST trial final analysis examined survival outcomes in patients with transplant-ineligible newly diagnosed multiple myeloma (NDMM) treated with lenalidomide and low-dose dexamethasone until disease progression (Rd continuous), Rd for 72 weeks
Autor:
Pieter Sonneveld, Eva Medvedova, Shinsuke Iida, Meletios A. Dimopoulos, Yu Nien Sun, Marcelo Capra, Merav Leiba, Liping Zhang, Jordan M. Schecter, Andrew Belch, P. Joy Ho, David Gomez, Richard Jansson, Pamela L. Clemens, Xu Steven Xu, Chang-Ki Min
Publikováno v:
Advances in Therapy
Advances in Therapy, 35(11), 1859-1872. Springer International Publishing AG
Advances in Therapy, 35(11), 1859-1872. Springer International Publishing AG
Introduction Daratumumab, a human IgG monoclonal antibody targeting CD38, has demonstrated activity as monotherapy and in combination with standard-of-care regimens in multiple myeloma. Population pharmacokinetic analyses were conducted to determine
Autor:
Gail T. McDonald, Bingshu E. Chen, Max Sherry, Marc Lalancette, Arleigh McCurdy, Sean Dolan, Richard Leblanc, Bethany Monteith, Irwindeep Sandhu, Engin Gul, Tony Reiman, Andrea Kew, Darrell White, Martha L Louzada, Andrew Belch, Christopher P. Venner, Christine Chen, Annette E. Hay, Donna E. Reece
Publikováno v:
Blood. 134:1871-1871
Background: Carfilzomib is effective in the treatment of relapsed and refractory multiple myeloma (RRMM). Questions remain regarding optimal dosing strategies and combinations. The MCRN-003/MYX.1 single arm phase II clinical trial of high-dose once w
Autor:
Nizar J. Bahlis, Matthew C. Cheung, Diane Brown, Thierry Facon, Chaim Shustik, Angela Dispenzieri, Darrell White, Kenneth C. Anderson, Suzanne Robinson, Stanley Kotey, Kevin W. Song, Christine Chen, Andrew Belch, Shankar Srinivasan, Axel Tosikyan
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 19:e225
Autor:
Franco Cavalli, Zvenyslava Masliak, Olga Samoilova, André Bosly, Tadeusz Robak, Huiqiang Huang, Angela Dascalescu, Jan Maciej Zaucha, Kateryna Vilchevskaya, Brendan Rooney, Andrew Belch, Charles M. Farber, Udomsak Bunworasate, Lixia Pei, Jan Novák, Johannes Drach, Helgi van de Velde
Publikováno v:
Leukemialymphoma. 59(4)
This post-hoc subanalysis of the LYM-3002 phase 3 study assessed the efficacy and safety of substituting vincristine in rituximab, cyclophosphamide, doxorubicin and prednisone (R-CHOP; n = 42) for bortezomib (VR-CAP; n = 38) in a subgroup of 80 mantl
Autor:
Alexandre Civet, Murielle Roussel, Michele Cavo, Meletios A. Dimopoulos, Angela Dispenzieri, Jae Hoon Lee, Michel Attal, Bruno M. Costa, Philippe Moreau, Eileen M Boyle, Philippe Rodon, Antoine Tinel, Yann Gaston-Mathé, Charles Dumontet, Jean Yves Mary, Thierry Facon, Juan José Lahuerta, Ann Van de Velde, Mohamad Mohty, Heinz Ludwig, Jan Van Droogenbroeck, Lugui Qiu, Aurore Perrot, Cyrille Hulin, Salomon Manier, Andrew Belch, Olivier Allangba
Publikováno v:
Leukemia
Infections are a major cause of death in patients with multiple myeloma. A post hoc analysis of the phase 3 FIRST trial was conducted to characterize treatment-emergent (TE) infections and study risk factors for TE grade >= 3 infection. The number of